Search
Interleukin-1 receptor-like 1
go.drugbank.com/bio_entities/BE0013861TargetHumansReceptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive immunity, contributing to tissue homeostasis and responses to environmental stresses together with coreceptor IL1RAP (PubMed:35238669). Its stimulation ...
Synonyms: DER4Elacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASHuman C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
Products: CİNRYZE 500 IU/5 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 2 ADETFosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsProducts: PREQUIM-F, EMEND ® IV 150MGThalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. … It has been reintroduced and used for a number of inflammatory disorders and cancers.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: α-N-phthalylglutaramide, (+-)-N-(2,6-dioxo-3-Piperidyl)phthalimideDT-DEC01
go.drugbank.com/drugs/DB19433ExperimentalDT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.
Selenomethionine
go.drugbank.com/drugs/DB11142ApprovedInvestigationalIt can be produced from post-structural modifications. … *In vivo*, selenomethionine plays an essential role in acting as an antioxidant, where it depletes reactive oxygen species (ROS) and aids in the formation and recycling of glutathione, another important
Mixtures: RE FAC-x, Vital-D Rx4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigationalFormestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. … It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Synonyms: 4-Androstene-7alpha-17beta-diol-3-one, 4,17beta-Dihydroxy-4-androstene-3-oneMelphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnMelphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230123] The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already.